CN112512550A - 一种TGF-β受体融合蛋白药物组合物及其用途 - Google Patents

一种TGF-β受体融合蛋白药物组合物及其用途 Download PDF

Info

Publication number
CN112512550A
CN112512550A CN201980050112.9A CN201980050112A CN112512550A CN 112512550 A CN112512550 A CN 112512550A CN 201980050112 A CN201980050112 A CN 201980050112A CN 112512550 A CN112512550 A CN 112512550A
Authority
CN
China
Prior art keywords
tgf
pharmaceutical composition
seq
fusion protein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980050112.9A
Other languages
English (en)
Inventor
田晨敏
李皓
刘洵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Suzhou Suncadia Biopharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112512550A publication Critical patent/CN112512550A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本公开公开了一种TGF‑β受体融合蛋白药物组合物及其用途。具体而言，该药物组合物包含在枸橼酸钠缓冲液中的TGF‑β受体融合蛋白，所述的TGF‑β受体融合蛋白包含PD‑L1抗体靶向部分和TGF‑βRII胞外区。除此之外，该药物组合物还可含有糖和非离子型表面活性剂。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201980050112.9A 2018-11-09 2019-11-08 一种TGF-β受体融合蛋白药物组合物及其用途 Pending CN112512550A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811328326 2018-11-09
CN2018113283261 2018-11-09
PCT/CN2019/116593 WO2020094122A1 (zh) 2018-11-09 2019-11-08 一种TGF-β受体融合蛋白药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN112512550A true CN112512550A (zh) 2021-03-16

Family

ID=70611696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050112.9A Pending CN112512550A (zh) 2018-11-09 2019-11-08 一种TGF-β受体融合蛋白药物组合物及其用途

Country Status (12)

Country Link
US (1) US20220017601A1 (zh)
EP (1) EP3878461A4 (zh)
JP (1) JP7436477B2 (zh)
KR (1) KR20210090643A (zh)
CN (1) CN112512550A (zh)
AU (1) AU2019374363A1 (zh)
BR (1) BR112021008288A2 (zh)
CA (1) CA3118415A1 (zh)
MX (1) MX2021005018A (zh)
TW (1) TWI829799B (zh)
UA (1) UA127771C2 (zh)
WO (1) WO2020094122A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112940134A (zh) * 2021-05-11 2021-06-11 正大天晴药业集团南京顺欣制药有限公司 针对PD-1和TGF-β的双功能蛋白
WO2023072043A1 (zh) * 2021-10-26 2023-05-04 正大天晴药业集团股份有限公司 ***的联用药物
CN116688115A (zh) * 2022-03-18 2023-09-05 上海齐鲁制药研究中心有限公司 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11802145B2 (en) 2019-10-21 2023-10-31 Nanjing Leads Biolabs Co., Ltd. Recombinant protein targeting PD-1 and TGFß
CN113754777A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗PD-L1/TGF-β融合蛋白
WO2022017487A1 (zh) * 2020-07-24 2022-01-27 迈威(上海)生物科技股份有限公司 TGF-β RII突变体及其融合蛋白
TW202214287A (zh) * 2020-08-24 2022-04-16 大陸商江蘇恒瑞醫藥股份有限公司 TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途
WO2022042715A1 (zh) * 2020-08-31 2022-03-03 杭州九源基因工程有限公司 靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
CN114437204A (zh) * 2020-10-30 2022-05-06 苏州盛迪亚生物医药有限公司 一种抗体或Fc融合蛋白的纯化方法
CN113289029B (zh) * 2021-05-20 2023-09-05 上海赛金生物医药有限公司 一种单克隆抗体-细胞因子融合蛋白制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101397343A (zh) * 2006-03-31 2009-04-01 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
WO2017084495A1 (zh) * 2015-11-17 2017-05-26 江苏恒瑞医药股份有限公司 Pd-l1抗体、其抗原结合片段及其医药用途
WO2017134592A1 (en) * 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
CN107513107A (zh) * 2016-06-15 2017-12-26 上海南方模式生物科技发展有限公司 抗肿瘤融合蛋白及其制法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232986T2 (de) 1991-10-31 2003-12-11 Whitehead Biomedical Inst TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG
DE69332026T2 (de) 1992-10-29 2002-10-31 Celtrix Pharma Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
JP2008526889A (ja) 2005-01-10 2008-07-24 リサーチ ディベロップメント ファウンデーション 癌治療のための標的化キメラ分子
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
JP6066732B2 (ja) 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CA3004695C (en) 2012-04-30 2020-08-04 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
CA2902830C (en) 2013-03-12 2023-09-19 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
EP3036262A4 (en) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
CN105934249A (zh) 2013-11-21 2016-09-07 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
NZ721364A (en) * 2014-02-10 2023-04-28 Merck Patent Gmbh Targeted tgfβ inhibition
US20170190778A1 (en) * 2014-05-27 2017-07-06 Trustees Of Boston University Inhibitors of fibroproliferative disorders and cancer
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
CN105435222B (zh) * 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
EP3344660A4 (en) * 2015-08-31 2019-07-03 National Research Council of Canada TGF-BETA-RECEPTOR-EKTODOMÄNENFUSIONSMOLEKÜLE AND USES THEREOF
MX2019008001A (es) * 2017-01-07 2019-09-09 Merck Patent Gmbh Regimenes de dosificacion y formas de dosificacion para inhibicion dirigida de factor beta de crecimiento transformante.
MX2019013023A (es) 2017-05-12 2019-12-18 Jiangsu Hengrui Medicine Co Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma.
BR112022007787A2 (pt) * 2019-11-01 2022-07-05 Ares Trading Sa Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101397343A (zh) * 2006-03-31 2009-04-01 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
WO2017084495A1 (zh) * 2015-11-17 2017-05-26 江苏恒瑞医药股份有限公司 Pd-l1抗体、其抗原结合片段及其医药用途
WO2017134592A1 (en) * 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
CN107513107A (zh) * 2016-06-15 2017-12-26 上海南方模式生物科技发展有限公司 抗肿瘤融合蛋白及其制法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YAN LAN: "Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β", 《SCIENCE TRANSLATIONAL MEDICINE》, vol. 10, 17 January 2018 (2018-01-17), pages 1 - 15, XP093111289, DOI: 10.1126/scitranslmed.aan5488 *
汪少芸: "《蛋白质纯化与分析技术》", 31 January 2014, 中国轻工业出版社, pages: 19 - 22 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112940134A (zh) * 2021-05-11 2021-06-11 正大天晴药业集团南京顺欣制药有限公司 针对PD-1和TGF-β的双功能蛋白
WO2023072043A1 (zh) * 2021-10-26 2023-05-04 正大天晴药业集团股份有限公司 ***的联用药物
CN116688115A (zh) * 2022-03-18 2023-09-05 上海齐鲁制药研究中心有限公司 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途
CN116688115B (zh) * 2022-03-18 2024-02-06 上海齐鲁制药研究中心有限公司 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途

Also Published As

Publication number Publication date
BR112021008288A2 (pt) 2021-08-10
CA3118415A1 (en) 2020-05-14
WO2020094122A1 (zh) 2020-05-14
KR20210090643A (ko) 2021-07-20
US20220017601A1 (en) 2022-01-20
MX2021005018A (es) 2021-06-15
TW202031279A (zh) 2020-09-01
EP3878461A1 (en) 2021-09-15
AU2019374363A1 (en) 2021-06-03
JP2022512862A (ja) 2022-02-07
EP3878461A4 (en) 2022-08-17
UA127771C2 (uk) 2023-12-27
JP7436477B2 (ja) 2024-02-21
TWI829799B (zh) 2024-01-21

Similar Documents

Publication Publication Date Title
TWI829799B (zh) 一種TGF-β受體融合蛋白醫藥組成物及其用途
CN111744007B (zh) 一种抗tigit抗体药物组合物及其用途
CN110538321B (zh) 一种cd47抗体药物组合物及其用途
CN110198739B (zh) 一种pd-l1抗体药物组合物及其用途
CN111356476B (zh) Lag-3抗体药物组合物及其用途
CN110732023B (zh) 一种her2抗体药物组合物及其用途
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
EP4190353A1 (en) Anti-pd-1 antibody pharmaceutical composition and use thereof
CN111375059A (zh) 一种抗gitr抗体药物组合物及其用途
CN112839961B (zh) 一种cd40抗体药物组合物及其用途
TW202144005A (zh) 一種抗ｏｘ４０抗體醫藥組成物及其用途
RU2791683C2 (ru) Фармацевтическая композиция слитого белка рецептора трансформирующего фактора роста бета и ее применение
WO2023040935A1 (zh) 一种含抗pvrig/tigit双特异性抗体的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045548

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20220215

Address after: 215126 No. 350, Fengli street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Applicant after: SUZHOU SUNCADIA BIOPHARMACEUTICALS Co.,Ltd.

Applicant after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Applicant after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Applicant before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Applicant before: Shanghai Hengrui Pharmaceutical Co., Ltd

TA01 Transfer of patent application right